
Danish biotechnology company Bavarian Nordic's vaccine against rabies has been tripped up by the covid-19 pandemic and resulting travel restrictions, the firm's Vice President Investor Relations & Communications Rolf Sass Sørensen tells Ritzau Finans following the publication of the firm's Q1 report.
In the first quarter, Bavarian Nordic presented retreated sales for the vaccines Rabipur/Rabavert for rabies and Encepur for tick-borne encephalitis (TBE).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app